Search results
Results from the WOW.Com Content Network
Glycerophospholipids are derived from glycerol-3-phosphate in a de novo pathway. [3] The term glycerophospholipid signifies any derivative of glycerophosphoric acid that contains at least one O-acyl, or O-alkyl, or O-alk-1'-enyl residue attached to the glycerol moiety. [4] The phosphate group forms an ester linkage to the glycerol.
A glycine reuptake inhibitor (GRI) is a type of drug which inhibits the reuptake of the neurotransmitter glycine by blocking one or more of the glycine transporters (GlyTs). ). Examples of GRIs include bitopertin (RG1678), iclepertin (BI-425809), ORG-24598, ORG-25935, ALX-5407, and sarcosine, which are selective GlyT1 blockers, and ORG-25435 and N-arachidonylglycine, which are selective GlyT2 blo
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. [ 5 ] [ 6 ] GIP-R is a member of the class B family of G protein coupled receptors . [ 7 ]
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1DAs, or incretin mimetics, [1] are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating.
Escitalopram, a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant.. Reuptake inhibitors (RIs) are a type of reuptake modulators.It is a drug that inhibits the plasmalemmal transporter-mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron.
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [5] [6] [10] Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary intervention (angioplasty with or without intracoronary stent placement). They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets.
This protocol is likely beneficial in women expected to be hyper-responders, and probably also those expected to be poor responders to ovarian hyperstimulation. [6] There is probably little or no difference between GnRH antagonist and GnRH agonist protocols in terms of live birth or risk of miscarriage but GnRH antagonists probably reduce the ...